Original Research
Published on 05 Apr 2023
Multiple doses of SHR-1222, a sclerostin monoclonal antibody, in postmenopausal women with osteoporosis: A randomized, double-blind, placebo-controlled, dose-escalation phase 1 trial
in Bone Research
- 8,245 views
- 5 citations






















